Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of IBI363 in advanced melanoma
CTR20233086Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IBI363 in melanoma, sponsored by InnoCare Pharma. Primary endpoints: Adverse events, Objective response rate and 5 more. Started Oct 2023; status: active.
02
Drugs
IBI363
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20233086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233086.